Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Argus Health
Dow
Healthtrust
US Department of Justice
Colorcon
Baxter
Johnson and Johnson
Cipla

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,198,925

« Back to Dashboard

Summary for Patent: 9,198,925
Title:Pharmaceutical formulations containing an SGLT2 inhibitor
Abstract: Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate ##STR00001## and a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release.
Inventor(s): Bindra; Dilbir S. (New Brunswick, NJ), Dali; Mandar V. (Bridgewater, NJ), Parab; Prakash V. (New Brunswick, NJ), Patel; Jatin M. (New Brunswick, NJ), Tao; Li (New Brunswick, NJ), Tejwani; Ravindra W. (Monmouth Junction, NJ), Vatsaraj; Nipa (New Brunswick, NJ), Wu; Yongmei (New Brunswick, NJ)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:14/267,984
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Dosage form;

Drugs Protected by US Patent 9,198,925

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca Ab BYDUREON PEN exenatide synthetic FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS 022200-002 Feb 28, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Astrazeneca Ab BYDUREON PEN exenatide synthetic FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS 022200-002 Feb 28, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe TREATMENT OF TYPE 2 DIABETES MELLITUS ➤ Subscribe
Astrazeneca Ab XIGDUO XR dapagliflozin propanediol; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205649-005 Jul 28, 2017 RX Yes No ➤ Subscribe ➤ Subscribe TREATMENT OF TYPE 2 DIABETES MELLITUS ➤ Subscribe
Astrazeneca Ab XIGDUO XR dapagliflozin propanediol; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205649-002 Oct 29, 2014 RX Yes No ➤ Subscribe ➤ Subscribe TREATMENT OF TYPE 2 DIABETES MELLITUS ➤ Subscribe
Astrazeneca Ab XIGDUO XR dapagliflozin propanediol; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205649-001 Oct 29, 2014 RX Yes No ➤ Subscribe ➤ Subscribe TREATMENT OF TYPE 2 DIABETES MELLITUS ➤ Subscribe
Astrazeneca Ab XIGDUO XR dapagliflozin propanediol; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205649-004 Oct 29, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe TREATMENT OF TYPE 2 DIABETES MELLITUS ➤ Subscribe
Astrazeneca Ab XIGDUO XR dapagliflozin propanediol; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205649-003 Oct 29, 2014 RX Yes No ➤ Subscribe ➤ Subscribe TREATMENT OF TYPE 2 DIABETES MELLITUS ➤ Subscribe
Astrazeneca Ab FARXIGA dapagliflozin propanediol TABLET;ORAL 202293-001 Jan 8, 2014 RX Yes No ➤ Subscribe ➤ Subscribe TREATMENT OF TYPE 2 DIABETES MELLITUS ➤ Subscribe
Astrazeneca Ab FARXIGA dapagliflozin propanediol TABLET;ORAL 202293-001 Jan 8, 2014 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Astrazeneca Ab FARXIGA dapagliflozin propanediol TABLET;ORAL 202293-002 Jan 8, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe TREATMENT OF TYPE 2 DIABETES MELLITUS ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,198,925

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,851,502 Pharmaceutical formulations containing an SGLT2 inhibitor ➤ Subscribe
8,221,786 Pharmaceutical formulations containing an SGLT2 inhibitor ➤ Subscribe
8,716,251 Pharmaceutical formulations containing an SGLT2 inhibitor ➤ Subscribe
8,361,972 Pharmaceutical formulations containing an SGLT2 inhibitor ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,198,925

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
South Korea 101772776 ➤ Subscribe
South Korea 20150038555 ➤ Subscribe
South Korea 101532188 ➤ Subscribe
South Korea 20140124874 ➤ Subscribe
South Korea 101502292 ➤ Subscribe
South Korea 20140069365 ➤ Subscribe
South Korea 101454051 ➤ Subscribe
Japan 5813147 ➤ Subscribe
South Korea 20090123964 ➤ Subscribe
Japan 2014111636 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Teva
QuintilesIMS
UBS
Daiichi Sankyo
US Department of Justice
Express Scripts
Argus Health
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot